ストックスクリーナーアプリを入手
0.9389
3.36%
0.0305
プレマーケット:
.95
0.0111
+1.18%
前日終値:
$0.9084
開ける：
$0.92
24時間の取引高:
215.77K
Relative Volume:
0.39
時価総額：
$77.37M
収益：
$38.70M
当期純損益:
$-117.88M
株価収益率:
-0.5523
EPS:
-1.7
ネットキャッシュフロー:
$-92.84M
1週間 パフォーマンス:
+3.27%
1か月 パフォーマンス:
+3.18%
6か月 パフォーマンス:
-24.28%
1年 パフォーマンス:
-61.52%
1日の値動き範囲:
$0.8897
$0.95
1週間の範囲:
$0.88
$0.95
52週間の値動き範囲:
$0.81
$3.62
Adicet Bio Inc Stock (ACET) Company Profile
ACET を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.9389 | 77.37M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-30 | 再開されました | Guggenheim | Buy |
| 2024-09-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-06-27 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-03-31 | 開始されました | SMBC Nikko | Outperform |
| 2022-03-08 | 開始されました | Truist | Buy |
| 2022-03-04 | 開始されました | Jefferies | Buy |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-14 | 開始されました | Canaccord Genuity | Buy |
| 2021-04-08 | 開始されました | Guggenheim | Buy |
| 2020-11-04 | 開始されました | B. Riley Securities | Buy |
| 2020-10-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-16 | 開始されました | Wedbush | Outperform |
すべてを表示
Adicet Bio Inc (ACET) 最新ニュース
Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by Jane Street Group LLC - Defense World
Geode Capital Management LLC Increases Position in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
Adicet Bio Advances First Gamma Delta CAR T Cell Therapy for Solid Tumors, Expands Autoimmune Trial - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Stake Reduced by State Street Corp - Defense World
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - Yahoo Finance
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World
Adicet Bio begins trial for kidney cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat
Adicet Bio begins trial for kidney cancer therapy - Investing.com
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - BioSpace
ACET stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ACET stock touches 52-week low at $0.89 amid market challenges - Investing.com Canada
Adicet Bio names new Chief Medical Officer By Investing.com - Investing.com Australia
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - BioSpace
Adicet Bio Names Dr. Julia Maltzman As Chief Medical Officer - Contract Pharma
Adicet Bio names new Chief Medical Officer - Investing.com
Adicet Bio Names Dr. Julia Maltzman as Chief Medical Officer - Contract Pharma
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com Canada
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 18.1% - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces CAR-T challenges - Investing.com
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Rises By 6.1% - MarketBeat
Adicet Bio Awards New Employee Stock Options at $1.13 Per Share in Inducement Grant | ACET Stock News - StockTitan
Adicet Bio clears debt with Banc of California By Investing.com - Investing.com South Africa
Adicet Bio clears debt with Banc of California - Investing.com India
Adicet Bio Clears Debts with Banc of California - TipRanks
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Has $56,000 Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio, Inc. Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Marketscreener.com
Adicet Bio Reports Q3 2024 Results and Clinical Progress - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease - CGTLive™
Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET - Nasdaq
Adicet Bio begins trial for innovative cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances Cancer and Autoimmune Trials - TipRanks
Adicet Bio begins trial for innovative cancer therapy - Investing.com
Adicet Bio Inc (ACET) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):